What is the recommended dose of WinRho (Rho(D) immune globulin) for a 28-week gestation pregnancy with O- blood type and negative antibodies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

WinRho Dosing for 28-Week Gestation Pregnancy with O- Blood Type and Negative Antibodies

For a 28-week gestation pregnancy with O- blood type and negative antibodies, the recommended dose of WinRho (Rho(D) immune globulin) is 300 μg (1500 IU) administered intramuscularly. 1, 2

Standard Antenatal Prophylaxis Protocol

  • At 28 weeks gestation, Rh-negative pregnant women without antibodies should receive 300 μg (1500 IU) of Rho(D) immune globulin intramuscularly as routine prophylaxis 1
  • This antenatal dose is a critical component of the two-dose protocol (28 weeks and postpartum) that reduces the rate of RhD alloimmunization from approximately 1.8% to between 0.1% and 0.2% 2
  • The intramuscular route is preferred for administration, preferably in the deltoid muscle of the upper arm or lateral thigh muscle 1
  • The gluteal region should be avoided as an injection site due to risk of sciatic nerve injury 1

Clinical Rationale

  • Fetal red blood cells display RhD antigens from as early as 6 weeks of gestation, making maternal sensitization possible throughout pregnancy 2
  • Studies show that fetomaternal hemorrhage occurs in 45% of women during the third trimester, which can lead to maternal sensitization if prophylaxis is not given 3
  • The 28-week timing is optimal as approximately 90% of alloimmunization cases in primigravidae are detectable after 28 weeks' gestation 3
  • Antenatal prophylaxis at 28 weeks provides protection against "silent" fetomaternal hemorrhage that may occur without clinical symptoms 3

Follow-up Dosing Requirements

  • A second dose of 300 μg (1500 IU) should be administered within 72 hours after delivery if the infant is Rh-positive 1, 2
  • If delivery occurs within 3 weeks after the 28-week dose, the postpartum dose may be withheld unless there is evidence of significant fetomaternal hemorrhage (>15 mL of fetal red blood cells) 1
  • For significant fetomaternal hemorrhage (>15 mL of fetal red blood cells), additional doses may be required, calculated by dividing the red blood cell volume by 15 mL to determine the number of syringes needed 1

Special Considerations

  • During the current WinRho shortage, pregnant women at 28 weeks gestation should still be prioritized for receiving available doses 4
  • If the typically used brand of RhIg is not available, an equivalent RhIg product (e.g., HyperRHO S/D, Rhophylac) may be substituted 4
  • The half-life of IgG is 23-26 days, so the 28-week dose provides protection through most of the third trimester 1

Important Caveats

  • Never administer WinRho intravenously for routine antenatal prophylaxis - only use the intramuscular route 1
  • Never administer the product to the neonate 1
  • Verbal or written informed consent should be obtained prior to administration of Rho(D) immune globulin 5
  • Women with "weak D" (Du-positive) should not receive anti-D prophylaxis 5
  • For O- women with their first pregnancy, this prophylaxis is particularly important as it prevents sensitization that could affect future pregnancies 6, 7

References

Guideline

Management Guidelines for Rh Negative Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The scientific basis of antenatal prophylaxis.

British journal of obstetrics and gynaecology, 1998

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Research

Anti-D administration in pregnancy for preventing rhesus alloimmunisation.

The Cochrane database of systematic reviews, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.